Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab induction in pediatric kidney transplant
NCT00240994Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2005
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in kidney transplant rejection, sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00240994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240994.